Malek F, Krueger P, Hatmi Z N, Malayeri A A, Faezipour H, O'Donnell R J
San Francisco Department of Orthopaedic Surgery UCSF Comprehensive Cancer Center Orthopaedic Oncology Service, University of California, San Francisco, CA 94115-1939, USA.
Int Orthop. 2006 Dec;30(6):495-8. doi: 10.1007/s00264-006-0146-3. Epub 2006 Aug 2.
Giant cell tumour (GCT) is a benign, but aggressive, primary tumour of the bone. The recurrence rate after surgical treatment has been reported to be as high as 50%. Many surgical techniques have been employed in the treatment of this tumour. More aggressive interventions, such as en bloc resection and bulk allograft or prosthetic reconstruction, are generally understood to be associated with lower rates of local recurrence. However, because of lessened morbidity, intralesional techniques have come to be favoured for this condition. In addition to curettage, various adjuvant procedures and packing materials have been advocated in order to control and reconstruct long bone defects secondary to this neoplasm. We report our experience with 40 long bone GCT patients treated with curettage, burring, bone grafting and no adjuvants between 1997 and 2002. There was a local recurrence rate of 32.5%, with most recurrences noted within the first 30 months after surgery. Minor complications were found in 18% of patients. The risk of local recurrence in this study is acceptable (within the range that has been historically reported for curettage and bone grafting). In cases where more resources are available, the addition of adjuvant therapies, as noted in the recent literature, may be beneficial. The results of this study should be considered when designing multicenteric studies in the future.
骨巨细胞瘤(GCT)是一种良性但具有侵袭性的原发性骨肿瘤。据报道,手术治疗后的复发率高达50%。治疗该肿瘤已采用了多种手术技术。一般认为,更积极的干预措施,如整块切除和大块同种异体骨移植或假体重建,与较低的局部复发率相关。然而,由于发病率降低,病灶内技术已成为这种情况的首选。除了刮除术,还提倡采用各种辅助程序和填充材料来控制和重建该肿瘤继发的长骨缺损。我们报告了1997年至2002年间对40例长骨GCT患者进行刮除、打磨、骨移植且未使用辅助剂的治疗经验。局部复发率为32.5%,大多数复发发生在术后前30个月内。18%的患者出现了轻微并发症。本研究中局部复发的风险是可以接受的(在历史上报道的刮除术和骨移植的范围内)。在有更多资源的情况下,如近期文献中所述,添加辅助治疗可能有益。在未来设计多中心研究时应考虑本研究结果。